Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2021

01-11-2021 | Adenovirus | Letter to the Editor

Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease

Author: Chutintorn Sriphrapradang

Published in: Endocrine | Issue 2/2021

Login to get access

Excerpt

Vera-Lastra et al. [1] and Zettinig et al. [2] recently reported four cases of Graves’ disease that developed after severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) BNT162b mRNA vaccination (Pfizer-BioNTech). I herein report a case with worsened Graves’ hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine. …
Literature
1.
O. Vera-Lastra, A. Ordinola Navarro, M.P. Cruz Domiguez, G. Medina, T.I. Sanchez Valadez, L.J. Jara, Two Cases of Graves’ Disease Following SARS-CoV-2 Vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid (2021). https://​doi.​org/​10.​1089/​thy.​2021.​0142.
2.
3.
Metadata
Title
Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease
Author
Chutintorn Sriphrapradang
Publication date
01-11-2021
Publisher
Springer US
Published in
Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02879-8

Other articles of this Issue 2/2021

Endocrine 2/2021 Go to the issue

Meta- Analysis

Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies

Original Article

Low reproducibility of equivocal categories of the Bethesda System for Reporting Thyroid Cytology makes the associated risk of malignancy specific to the diagnostic center

Original Article

Association of triglyceride–glucose index with intra- and extra-cranial arterial stenosis: a combined cross-sectional and longitudinal analysis

Original Article

Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors

Viewpoint

Thyroid testing paradigm switch from thyrotropin to thyroid hormones—Future directions and opportunities in clinical medicine and research

Review

A practical approach to normocalcemic primary hyperparathyroidism
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits